Inventiva S.A.(IVA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

IVA Inventiva S.A.

Trading 11-22 09:49:06 EST

2.59

-0.01

-0.39%

High2.59	Low2.55	Vol6.12K
Open2.56	D1 Closing2.60	Amplitude1.53%
Mkt Cap225.51M	Tradable Cap47.07M	Total Shares87.08M
T/O15.83K	T/O Rate0.03%	Tradable Shares18.17M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"IVA","market":"US","secType":"STK","nameCN":"Inventiva S.A.","latestPrice":2.5898,"timestamp":1732286783276,"preClose":2.6,"halted":0,"volume":6118,"delay":0,"floatShares":18174220,"shares":87077695,"eps":-2.218419,"marketStatus":"Trading","change":-0.0102,"latestTime":"11-22 09:49:06 EST","open":2.555,"high":2.5898,"low":2.55,"amount":15825.5792674,"amplitude":0.015308,"askPrice":2.66,"askSize":600,"bidPrice":2.56,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-2.218419,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1732309200000},"marketStatusCode":2,"adr":0,"adrRate":1,"listingDate":1594353600000,"exchange":"NASDAQ","adjPreClose":2.6,"postHourTrading":{"tag":"盘后","latestPrice":2.66,"preClose":2.66,"latestTime":"19:25 EST","volume":15,"amount":37.5505,"timestamp":1732235120059},"volumeRatio":8.402071},"requestUrl":"/m/hq/s/IVA/wiki","defaultTab":"wiki","newsList":[{"id":"2485422228","title":"Inventiva S.A reports 9M results","url":"https://stock-news.laohu8.com/highlight/detail?id=2485422228","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485422228?lang=en_us&edition=fundamental","pubTime":"2024-11-22 05:51","pubTimestamp":1732225870,"startTime":"0","endTime":"0","summary":"Inventiva S.A press release : 9M Revenue of 1.3B. As of September 30, 2024, the Company’s cash and cash equivalents amounted to 13.9 million, compared to cash and cash equivalents at 26.9 million, short-term deposit4 at 0.01 million, and long-term deposit5 at 9.0 million as of December 31, 2023. Net cash used in operating activities amounted to  million in the first nine months of 2024, compared to  million for the same period in 2023 down by 7.0% . R&D expenses, mainly driven by the development of lanifibranor in MASH/NASH, for the first nine months of 2024 amounted to 71.7 million and were down 10.0% compared to the 79.6 million for the first nine months of 2023.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4319073-inventiva-sa-reports-9m-results","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["IVA","BK4139"],"gpt_icon":0},{"id":"2485261784","title":"Inventiva’s Financial Position and Future Prospects","url":"https://stock-news.laohu8.com/highlight/detail?id=2485261784","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485261784?lang=en_us&edition=fundamental","pubTime":"2024-11-22 05:47","pubTimestamp":1732225632,"startTime":"0","endTime":"0","summary":"Inventiva (IVA) has released an update. Inventiva, a clinical-stage biopharmaceutical company, has reported a cash position of €13.9 million as of ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/inventivas-financial-position-and-future-prospects?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/inventivas-financial-position-and-future-prospects?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IVA","BK4139"],"gpt_icon":0},{"id":"2485423913","title":"Inventiva Reports Revenues Of €1.3 Million For The First 9-Months Of 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2485423913","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485423913?lang=en_us&edition=fundamental","pubTime":"2024-11-22 05:16","pubTimestamp":1732223770,"startTime":"0","endTime":"0","summary":"Cash and cash equivalents at €13.9 million, as of September 30, 2024.Revenues of €1.3 million for the first nine months of 2024.On July 18, 2024, Inventiva issued royalty certificates for an amount of €20.1","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/42123657/inventiva-reports-revenues-of-1-3-million-for-the-first-9-months-of-2024","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IVA"],"gpt_icon":0},{"id":"2485142847","title":"Inventiva reports 2024 Third Quarter Financial Information¹","url":"https://stock-news.laohu8.com/highlight/detail?id=2485142847","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485142847?lang=en_us&edition=fundamental","pubTime":"2024-11-22 05:00","pubTimestamp":1732222800,"startTime":"0","endTime":"0","summary":"Revenues of 1.3 million for the first nine months of 2024.On July 18, 2024, Inventiva issued royalty certificates for an amount of 20.1 million.As of September 30, 2024, the Company’s cash and cash equivalents amounted to 13.9 million, compared to cash and cash equivalents at 26.9 million, short-term deposit4 at 0.01 million, and long-term deposit5 at 9.0 million as of December 31, 2023.Net cash generated from investing activities for the first nine months of 2024 amounted to 8.7 million, compared to (3.5) million used for the same period in 2023. The change is mostly due to the variation in term deposits between both periods.Net cash generated from financing activities for the first nine months of 2024 amounted to 42.3 mi","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/XY_QbwknG0g_dMiiDPyLvw--~B/aD0xNzg7dz0zNzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/a1497e6e1366ecc45a71fef2ce2e7535","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/XY_QbwknG0g_dMiiDPyLvw--~B/aD0xNzg7dz0zNzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/a1497e6e1366ecc45a71fef2ce2e7535"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/inventiva-reports-2024-third-quarter-210000492.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","IVA","BK4134","III"],"gpt_icon":0},{"id":"2485171270","title":"Inventiva Reports Voting Rights and Advances Clinical Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2485171270","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485171270?lang=en_us&edition=fundamental","pubTime":"2024-11-21 05:54","pubTimestamp":1732139694,"startTime":"0","endTime":"0","summary":"Inventiva (IVA) has released an update. Inventiva, a clinical-stage biopharmaceutical company, has reported its total voting rights and shares form...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/inventiva-reports-voting-rights-and-advances-clinical-trials?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/inventiva-reports-voting-rights-and-advances-clinical-trials?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","IVA"],"gpt_icon":0},{"id":"2485171268","title":"Inventiva Prepares for Key General Meeting and Financing Plans","url":"https://stock-news.laohu8.com/highlight/detail?id=2485171268","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485171268?lang=en_us&edition=fundamental","pubTime":"2024-11-21 05:54","pubTimestamp":1732139684,"startTime":"0","endTime":"0","summary":"Inventiva (IVA) has released an update. Inventiva is gearing up for its Combined General Meeting on December 11, 2024, where shareholders will vote...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/inventiva-prepares-for-key-general-meeting-and-financing-plans?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/inventiva-prepares-for-key-general-meeting-and-financing-plans?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","IVA"],"gpt_icon":0},{"id":"2485654173","title":"Statement of total voting rights and shares forming the company’s share capital as of November 4, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2485654173","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485654173?lang=en_us&edition=fundamental","pubTime":"2024-11-21 05:00","pubTimestamp":1732136400,"startTime":"0","endTime":"0","summary":"The total number of gross  voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.The total number of net  voting rights is calculated without taking into account shares for which voting rights have been suspended, i.e. treasury shares . It is released in order to ensure that the public is properly informed.The Company has a scientific team of approximately 90 people with deep expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, and clinical development. It owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly-owned research and development facility.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/XY_QbwknG0g_dMiiDPyLvw--~B/aD0xNzg7dz0zNzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/a1497e6e1366ecc45a71fef2ce2e7535","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/XY_QbwknG0g_dMiiDPyLvw--~B/aD0xNzg7dz0zNzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/a1497e6e1366ecc45a71fef2ce2e7535"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/statement-total-voting-rights-shares-210000892.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","IVA"],"gpt_icon":0},{"id":"2485125795","title":"Five9, Inc (FIVN) Expands AI Suite: Next-Gen AI Agents Revolutionize Customer Experience","url":"https://stock-news.laohu8.com/highlight/detail?id=2485125795","media":"Insider Monkey","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485125795?lang=en_us&edition=fundamental","pubTime":"2024-11-21 01:52","pubTimestamp":1732125122,"startTime":"0","endTime":"0","summary":"We recently published a list of 15 AI News Stories Shaking Up Wall Street. In this article, we are going to take a look at where Five9, Inc.  stands against other AI news stories shaking up Wall Street.U.S. President Joe Biden met with China’s President Xi Jinping at the APEC Summit in Lima, Peru, on November 16. According to the White House, the two reached an agreement affirming that human beings, not artificial intelligence, should make decisions about the use of nuclear weapons.“The two leaders affirmed the need to maintain human control over the decision to use nuclear weapons. The two leaders also stressed the need to consider carefully the potential risks and develop AI technology in the military field in a prudent and responsible manner”.READ ALSO: 15 AI News You Must Read Todayand15 AI News That Broke The Internet. This agreement marks a groundbreaking step in addressing two complex and challenging topics: nuclear weapons and artificial intelligence. However, it remains unclea","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Ad.yZHMd4u34PqFQ7LE_Pw--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/3f9695b288b943dc1be35cb72c415c03","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Ad.yZHMd4u34PqFQ7LE_Pw--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/3f9695b288b943dc1be35cb72c415c03"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/five9-inc-fivn-expands-ai-175202875.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MNQmain","TQQQ","BK4588",".IXIC","QID","FIVN","LU2286300806.USD","SQQQ","QLD","IVA","NQmain","GEN","BK4585","BK4097","PSQ","BK4023","BK4139"],"gpt_icon":1},{"id":"2484944773","title":"Travel Services Company Deploys Verint AI-Powered Self-Service, Driving $10 Million Annual Savings","url":"https://stock-news.laohu8.com/highlight/detail?id=2484944773","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484944773?lang=en_us&edition=fundamental","pubTime":"2024-11-19 21:30","pubTimestamp":1732023000,"startTime":"0","endTime":"0","summary":"Verint Intelligent Virtual Assistant Increases Containment from 10% to 50% in One Month. MELVILLE, N.Y., November 19, 2024----Verint , The CX Automation Company, today announced that a major U.S. travel services company deployed Verint AI-powered Intelligent Voice Assistant  to replace their legacy telephony IVR  solution and achieved strong AI business outcomes. The company increased containment in self-service from 10% to 50% of their telephony traffic within the first month, driving $10 million in annual savings.The company was using a legacy touch-tone IVR for self-service across 4 million calls annually. Verint IVA delivered best-of-breed intent recognition as well as integrations to back-end systems, such as CRM and location services, to accurately respond to customer questions. As a result, call containment within the self-service channel significantly increased.\"Verint IVA is revolutionizing the approach to telephony self-service,\" says Verint’s Heather Richards, vice president","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/sNjhgoZqqAzFYudgM_WcAQ--~B/aD0zOTA7dz0xNTAxO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/4a5a22418c8d69382c1b590852c8297c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/sNjhgoZqqAzFYudgM_WcAQ--~B/aD0zOTA7dz0xNTAxO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/4a5a22418c8d69382c1b590852c8297c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/travel-services-company-deploys-verint-133000457.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["VRNT","LU0566484027.USD","BK4139","IVA","CX","LU1559883803.SGD","BK4023","BK4011"],"gpt_icon":1},{"id":"2484367186","title":"Alight to Enhance the Employee Experience with Launch of Alight Worklife® on Microsoft Teams","url":"https://stock-news.laohu8.com/highlight/detail?id=2484367186","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484367186?lang=en_us&edition=fundamental","pubTime":"2024-11-18 21:30","pubTimestamp":1731936600,"startTime":"0","endTime":"0","summary":"Alight’s new Teams integration, developed in collaboration with Avanade, enables employers to deliver a seamless, connected employee experience. CHICAGO, November 18, 2024----Alight, Inc. , a leading cloud-based human capital and technology-enabled services provider and Avanade, a leading Microsoft expert, today announced a collaboration to integrate Alight Worklife  with Microsoft Teams. This novel integration empowers employers to further enhance their employee’s benefits experience by providing seamless access to benefits and wellbeing information directly within the Teams platform.The application will be available to employers who utilize both Teams and Alight Worklife, beginning with the next release of the Alight Worklife platform. By integrating benefits access directly into employees’ daily software, the Alight Worklife integration for Teams will simplify benefits access, boost awareness, enable greater utilization, and enhance the overall employee experience and wellbeing.Inte","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/X6BqZ_SluYU4pjOr9PJPJA--~B/aD0yNzU7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/f9646de7db226fb2e167259048d0e140","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/X6BqZ_SluYU4pjOr9PJPJA--~B/aD0yNzU7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/f9646de7db226fb2e167259048d0e140"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alight-enhance-employee-experience-launch-133000677.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0170899867.USD","LU2362541513.USD","LU1340139317.AUD","LU0957791311.USD","LU0757359368.USD","LU0784385170.HKD","LU1815333072.USD","IE000ITXATA3.USD","ALIT","LU0057025933.USD","LU2362540622.SGD","SG9999004303.SGD","IE0004091025.USD","LU2404859667.USD","LU2463028550.USD","LU1564329032.USD","LU1934455277.USD","LU0171293334.USD","IE00BK4W5M84.HKD","BK4139","LU2089284900.SGD","LU1814569148.SGD","LU2125154778.USD","IE00BLSP4452.SGD","LU1989763005.USD","LU0006306889.USD","LU1582987597.SGD","BK4538","IE00BFXG0V08.USD","IE00BMPRXQ63.HKD","IVA","LU0095938881.EUR","LU0081259029.USD","LU1564329115.USD","LU2430703178.SGD","LU0784383803.USD","GB00BDT5M118.USD","GB00B4QBRK32.GBP","BK4130","IE00BN8TJ469.HKD","MSFT","LU2403377893.USD","LU1934455863.HKD","LU1366333091.USD","LU2452424414.USD","LU1280957306.USD","SG9999014880.SGD","LU0795875086.SGD","GRO","LU2237443895.HKD"],"gpt_icon":1},{"id":"2483364295","title":"Inventiva’s Phase 2 Results Boost Hope for MASH Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2483364295","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483364295?lang=en_us&edition=fundamental","pubTime":"2024-11-16 05:57","pubTimestamp":1731707826,"startTime":"0","endTime":"0","summary":"Inventiva (IVA) has released an update. Inventiva has released promising results from its Phase 2 LEGEND study, showing that the combination of lan...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/inventivas-phase-2-results-boost-hope-for-mash-treatment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/inventivas-phase-2-results-boost-hope-for-mash-treatment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IVA","BK4139","HOPE","BK4211"],"gpt_icon":0},{"id":"2483538169","title":"Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® late-breaker session","url":"https://stock-news.laohu8.com/highlight/detail?id=2483538169","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483538169?lang=en_us&edition=fundamental","pubTime":"2024-11-16 05:00","pubTimestamp":1731704400,"startTime":"0","endTime":"0","summary":"Data will be presented on Monday, November 18th as a late breaker poster at the American Association for the Study of Liver Diseases  The Liver Meeting 2024 in San Diego.LEGEND achieved its primary efficacy endpoint by significantly lowering HbA1c level in both the lanifibranor arm and in the lanifibranor with empagliflozin arm compared to placebo.50% percent of patients saw their HbA1c levels below 6.5% at week 24 following treatment with lanifibranor alone or in combination with empagliflozin.Dr. Nezam  Afdhal, Chief of Gastroenterology, Beth Israel Deaconess Medical Center, Professor of Medicine, Harvard Medical School, said: “It is frequently overlooked that MASH is a liver manifestation of insulin resistance. The exciting new data from the LEGEND study, which evaluates the combination of lanifibranor and empagliflozin, confirms that lanifibranor has the potential to target the underlying biology of the disease. Additionally, LEGEND should alleviate the concerns about weight gain, ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/XY_QbwknG0g_dMiiDPyLvw--~B/aD0xNzg7dz0zNzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/a1497e6e1366ecc45a71fef2ce2e7535","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/XY_QbwknG0g_dMiiDPyLvw--~B/aD0xNzg7dz0zNzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/a1497e6e1366ecc45a71fef2ce2e7535"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/inventiva-present-data-final-analysis-210000345.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","IVA"],"gpt_icon":0},{"id":"2483609098","title":"Verint Systems Inc. (VRNT): Transforming Customer Engagement with AI, Saving $10.5 Million Annually for a Leading Telecom Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2483609098","media":"Insider Monkey","labels":["Business Data"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483609098?lang=en_us&edition=fundamental","pubTime":"2024-11-14 08:55","pubTimestamp":1731545722,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 15 AI News That Broke The Internet.In this article, we are going to take a look at where Verint Systems Inc.  stands against the other AI stocks that broke the Internet.One conversation gaining traction in Silicon Valley these days is how the advancement of Generative AI models is slowing down. Deirdre Bosa takes a look at the matter in CNBC’s TechCheck, revealing how rapid genAI advancements are now showing signs of deceleration. She notes how the quality of improvement in OpenAI's upcoming model, Orion, is expected to be smaller than the leap from ChatGPT-3 to ChatGPT-4. This smaller advancement is largely due to a limited supply of training data, a key factor that could significantly affect how investors view AI companies.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/1IA5D3fr9KHMV9XeAelegQ--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/034484968a17b417afb2d104b7fb01fe","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/1IA5D3fr9KHMV9XeAelegQ--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/034484968a17b417afb2d104b7fb01fe"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/verint-systems-inc-vrnt-transforming-005522001.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Business Data","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4538","IE00BKPKM429.USD","BK4503","LU0187121727.USD","TQQQ","IE00BJTD4V19.USD","MNQmain","LU0096364046.USD","LU0130102774.USD","LU0052756011.USD",".IXIC","LU0130103400.USD","LU0109391861.USD","BK4077","SSI","BK4566","QLD","IE00BK4W5M84.HKD","LU0128525929.USD","PSQ","BK4139","IVA","LU0097036916.USD","LU0154236417.USD","LU0198837287.USD","QID","LU0215105999.USD","IE0034235303.USD","NQmain","IE00BJTD4N35.SGD","LU0061475181.USD","LU0225283273.USD","LU0029864427.USD","BK4592","BK4023","BK4573","LU0106261372.USD","LU0234570918.USD","LU0149725797.USD","GOOGL","LU0130518102.USD","LU0077335932.USD","BK4534","BK4588","LU1559883803.SGD","SQQQ","IE00BZ1G4Q59.USD","IE00BK4W5L77.USD","VRNT"],"gpt_icon":1},{"id":"2483880478","title":"Five9 Unveils AI Agents to Redefine Hyper-Personalized Self-Service CX","url":"https://stock-news.laohu8.com/highlight/detail?id=2483880478","media":"Business Wire","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483880478?lang=en_us&edition=fundamental","pubTime":"2024-11-13 21:00","pubTimestamp":1731502800,"startTime":"0","endTime":"0","summary":"Five9 AI Agents blend AI models to automate self-service while giving businesses greater control, flexibility, and trust. Next-Gen Intelligent Virtual Agents combined with Generative AI to reduce interactions that need to be routed to human agents. BARCELONA, Spain, November 13, 2024----Five9 CX Summit -- Five9 , provider of the Intelligent CX Platform, today announced the expansion of its Five9 Genius AI suite with the launch of Five9 AI Agents, the next-generation of Five9 Intelligent Virtual Agents  which incorporates Generative AI. Five9 AI Agents empower businesses to create chat and voice bots that combine the conversational abilities of a human with the speed and extensive knowledge of AI. This will enable businesses to reduce the need for live agent interactions. Five9 AI Agents provides a conceptual dial-of-trust that allows businesses to balance flexibility and control to meet customers’ needs by blending generative AI with traditional pre-defined AI in the same conversation.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/6.njTkd8SSV2uYI.a3VEGg--~B/aD0yNTI7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/e900c35c7afe3d0a98150a1408e2ab6c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/6.njTkd8SSV2uYI.a3VEGg--~B/aD0yNTI7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/e900c35c7afe3d0a98150a1408e2ab6c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/five9-unveils-ai-agents-redefine-130000182.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IVA","CX","BK4023","FIVN","BK4011","BK4139"],"gpt_icon":1},{"id":"2482084751","title":"Inventiva Sa : UBS Initiates Coverage With Neutral Rating; Price Target $3","url":"https://stock-news.laohu8.com/highlight/detail?id=2482084751","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482084751?lang=en_us&edition=fundamental","pubTime":"2024-11-12 23:32","pubTimestamp":1731425567,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241112:nFWN3MJ1FH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IVA","BK4139"],"gpt_icon":0},{"id":"2482478421","title":"Top Telecommunications Company Reports $10.5 Million Annual Savings from Verint AI-Powered Voice Self-Service","url":"https://stock-news.laohu8.com/highlight/detail?id=2482478421","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482478421?lang=en_us&edition=fundamental","pubTime":"2024-11-11 21:30","pubTimestamp":1731331800,"startTime":"0","endTime":"0","summary":"MELVILLE, N.Y., November 11, 2024----Verint , The CX Automation Company, today announced that a top telecommunications company reported annual savings of more than $10.5 million by using the Verint Intelligent Virtual Assistant  to power their contact center telephony self-service.The company replaced their old telephony-driven IVR technology with Verint AI-powered IVA to deliver tangible business outcomes, including improving its self-service containment rate and elevating the service experience for consumers.This press release contains \"forward-looking statements,\" including statements regarding expectations, predictions, views, opportunities, plans, strategies, beliefs and statements of similar effect relating to Verint Systems Inc. These forward-looking statements are not guarantees of future performance and they are based on management's expectations that involve a number of risks, uncertainties and assumptions, any of which could cause actual results to differ materially from tho","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/lIpuBR5BP53.Wzlz17hzHQ--~B/aD0zOTA7dz0xNTAxO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/dce47230b10cda28d00584a479511cd2","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/lIpuBR5BP53.Wzlz17hzHQ--~B/aD0zOTA7dz0xNTAxO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/dce47230b10cda28d00584a479511cd2"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/top-telecommunications-company-reports-10-133000973.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["WRD","BK4011","IVA","LU1559883803.SGD","VRNT","BK4139","BK4023","CX","LU0566484027.USD"],"gpt_icon":0},{"id":"2480859735","title":"Inventiva’s Strategic Moves at Upcoming General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2480859735","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480859735?lang=en_us&edition=fundamental","pubTime":"2024-11-04 21:57","pubTimestamp":1730728634,"startTime":"0","endTime":"0","summary":"Inventiva (IVA) has released an update. Inventiva is set to hold its Ordinary and Extraordinary General Meeting on December 11, 2024, where shareho...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/inventivas-strategic-moves-at-upcoming-general-meeting?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/inventivas-strategic-moves-at-upcoming-general-meeting?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IVA","BK4139"],"gpt_icon":0},{"id":"2479618247","title":"Inventiva Gains Positive Nod for Lanifibranor Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2479618247","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479618247?lang=en_us&edition=fundamental","pubTime":"2024-10-31 05:19","pubTimestamp":1730323173,"startTime":"0","endTime":"0","summary":"Inventiva (IVA) has released an update. Inventiva has announced a positive recommendation from the Data Monitoring Committee for its NATiV3 Phase 3...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/inventiva-gains-positive-nod-for-lanifibranor-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/inventiva-gains-positive-nod-for-lanifibranor-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IVA","BK4139"],"gpt_icon":0},{"id":"2479656752","title":"Inventiva announces the positive recommendation of the fifth DMC of the NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASH","url":"https://stock-news.laohu8.com/highlight/detail?id=2479656752","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479656752?lang=en_us&edition=fundamental","pubTime":"2024-10-31 04:00","pubTimestamp":1730318400,"startTime":"0","endTime":"0","summary":"The Data Monitoring Committee recommended to continue the clinical trial without modification of the current protocol, based on the pre-planned review of safety data.Lanifibranor, Inventiva’s lead product candidate, is an orally-available small molecule that acts to induce anti-fibrotic, anti-inflammatory and beneficial vascular and metabolic changes in the body by activating all three peroxisome proliferator-activated receptor  isoforms, which are well-characterized nuclear receptor proteins that regulate gene expression. Lanifibranor is a PPAR agonist that is designed to target all three PPAR isoforms in a moderately potent manner, with a well-balanced activation of PPARα and PPARδ, and a partial activation of PPARγ. While there are other PPAR agonists that target only one or two PPAR isoforms for activation, lanifibranor is the only pan-PPAR agonist in clinical development for the treatment of MASH. Inventiva believes that lanifibranor’s moderate and balanced pan-PPAR binding profil","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/XY_QbwknG0g_dMiiDPyLvw--~B/aD0xNzg7dz0zNzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/a1497e6e1366ecc45a71fef2ce2e7535","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/XY_QbwknG0g_dMiiDPyLvw--~B/aD0xNzg7dz0zNzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/a1497e6e1366ecc45a71fef2ce2e7535"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/inventiva-announces-positive-recommendation-fifth-200000980.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","IVA"],"gpt_icon":0},{"id":"2477343912","title":"TRU Recognition emerges as a key player in booming intelligent video analytics market","url":"https://stock-news.laohu8.com/highlight/detail?id=2477343912","media":"Stockheads","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477343912?lang=en_us&edition=fundamental","pubTime":"2024-10-23 10:24","pubTimestamp":1729650240,"startTime":"0","endTime":"0","summary":"TRU Recognition specialises in Vision AI and aggerating intelligent video analytics models and solutions. The company increases operational efficiency, decreases costs and mitigates risks across retail, resources, healthcare, and transportation. Partnership with Ericsson positions TRU for growth in a booming market","market":"us","thumbnail":"https://stockhead.com.au/wp-content/uploads/2024/10/GettyImages-1291181797-1200_x_675-640x360.jpg","type":0,"news_type":0,"thumbnails":["https://stockhead.com.au/wp-content/uploads/2024/10/GettyImages-1291181797-1200_x_675-640x360.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stockhead.com.au/tech/tru-recognition-emerges-as-a-key-player-in-booming-intelligent-video-analytics-market/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockheads_stock","symbols":["BK4591","IVA","LU1169590202.USD","LU1989764748.USD","SGXZ23171101.USD","BK4515","ERIC","SG9999004303.SGD","TRU","LU1989764664.SGD","LU1169589451.USD","BK4123","BK4020","BK4139","BK4554"],"gpt_icon":0}],"profile":{"websiteUrl":"http://inventivapharma.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":-0.0256},{"period":"3month","weight":0.1083},{"period":"6month","weight":-0.2323},{"period":"1year","weight":-0.3338},{"period":"ytd","weight":-0.411}],"compareEarnings":[{"period":"1week","weight":0.0005},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.0561},{"period":"6month","weight":0.1213},{"period":"1year","weight":0.3047},{"period":"ytd","weight":0.249}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of mucopolysaccharidoses type VI disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.033773},{"month":2,"riseRate":0.5,"avgChangeRate":-0.02424},{"month":3,"riseRate":0,"avgChangeRate":-0.114231},{"month":4,"riseRate":0,"avgChangeRate":-0.166714},{"month":5,"riseRate":0.75,"avgChangeRate":0.155722},{"month":6,"riseRate":0.25,"avgChangeRate":-0.133608},{"month":7,"riseRate":0.25,"avgChangeRate":-0.09757},{"month":8,"riseRate":0.2,"avgChangeRate":0.009571},{"month":9,"riseRate":0.4,"avgChangeRate":-0.030876},{"month":10,"riseRate":0.8,"avgChangeRate":0.137564},{"month":11,"riseRate":0.2,"avgChangeRate":-0.027163},{"month":12,"riseRate":1,"avgChangeRate":0.075845}],"exchange":"NASDAQ","name":"Inventiva S.A.","nameEN":"Inventiva S.A."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Inventiva S.A.(IVA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Inventiva S.A.(IVA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Inventiva S.A.,IVA,Inventiva S.A.股票,Inventiva S.A.股票老虎,Inventiva S.A.股票老虎国际,Inventiva S.A.行情,Inventiva S.A.股票行情,Inventiva S.A.股价,Inventiva S.A.股市,Inventiva S.A.股票价格,Inventiva S.A.股票交易,Inventiva S.A.股票购买,Inventiva S.A.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Inventiva S.A.(IVA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Inventiva S.A.(IVA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction